Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19

A new coronavirus associated with human respiratory disease in China

(2020) Fan Wu et al.   NATURE

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov

(2020) Jihan Huang et al.   Drug Design Development and Therapy

Organ function support in patients with coronavirus disease 2019: Tongji experience

(2020) Yong Li et al.   Frontiers of Medicine

COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)

(2020) Yang Song et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Remdesivir for severe covid-19: a clinical practice guideline

(2020) Bram Rochwerg et al.   BMJ-British Medical Journal

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

(2020) Muhammad Adnan Shereen et al.   Journal of Advanced Research

Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections

(2019) Aslaa Ahmed et al.   ANTIVIRAL RESEARCH

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

(2019) Egor Tchesnokov et al.   Viruses-Basel

Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C

(2018) Lesley J. Scott   DRUGS

Emtricitabine + tenofovir alafenamide for the treatment of HIV

(2017) Katya C. Corado et al.   EXPERT OPINION ON PHARMACOTHERAPY

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Sample sizes in dosage investigational clinical trials: a systematic evaluation

(2015) Jihan Huang et al.   Drug Design Development and Therapy

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

(2014) Travis K. Warren et al.   NATURE

Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro

(2014) Rui-Rui Wang et al.   PLoS One

Design of inhibitors of influenza virus membrane fusion: Synthesis, structure–activity relationship and in vitro antiviral activity of a novel indole series

(2013) Virginia Brancato et al.   ANTIVIRAL RESEARCH

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

(2013) David Alan Herbst et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

(2013) Yutong Jiang et al.   JOURNAL OF MEDICINAL CHEMISTRY

High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells

(2012) Yoon-Ok Jang et al.   BMC GASTROENTEROLOGY

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

(2011) Choongho Lee et al.   VIROLOGY